Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEAMARK first-line triplet therapy study in BRAF V600E-mutant MSI-H/dMMR metastatic colorectal cancer
NL-OMON60787Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of encorafenib, cetuximab and pembrolizumab in colorectal cancer (CRC) and colorectal adenocarcinoma (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Oct 2022; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON60787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60787.